Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target

Area of Science:

• Oncology
• Pharmacology
• Computational Chemistry

Background:

• HER2-positive breast cancer is an aggressive subtype affecting approximately 30% of patients.
• Current HER2-targeting therapies (trastuzumab, pertuzumab, lapatinib, ado-trastuzumab emtansine) face challenges with resistance and non-response.
• There is a critical need for novel therapeutic strategies for HER2-positive breast cancer.

Purpose of the Study:

• To screen phytochemicals from Ginkgo biloba for potential therapeutic activity against HER2.
• To identify novel lead compounds for HER2-positive breast cancer treatment using molecular docking.
• To evaluate the binding affinity of selected phytochemicals with the HER2 protein.

Main Methods:

• Literature review to identify 25 phytochemicals from Ginkgo biloba.
• In silico molecular docking simulations were performed to assess binding interactions with HER2.
• Binding energy calculations were used to quantify the affinity of phytochemicals to HER2.

Main Results:

• Cianidanol, a phytochemical from Ginkgo biloba, demonstrated significant binding affinity to HER2.
• The binding energy for cianidanol with HER2 was calculated to be -8.2 kcal/mol.
• This suggests cianidanol as a potential candidate for further investigation in HER2-positive breast cancer.

Conclusions:

• Cianidanol exhibits favorable binding properties with HER2, indicating its potential as a novel therapeutic agent.
• Phytochemical screening using molecular docking offers a promising approach to discover new treatments for HER2-positive breast cancer.
• Further experimental validation is warranted to explore the therapeutic efficacy of cianidanol.